LY2608204,
1234703-40-2,
LY-2608204,
UNII-5A0L003HEY,
5A0L003HEY,
LY 2608204,
(1R,2S)-2-Cyclohexyl-1-(4-cyclopropylsulfonylphenyl)-N-[5-(2-pyrrolidin-1-ylethylsulfanyl)-1,3-thiazol-2-yl]cyclopropane-1-carboxamide,
(1R,2S)-2-cyclohexyl-1-[4-(cyclopropanesulfonyl)phenyl]-N-(5-{[2-(pyrrolidin-1-yl)ethyl]sulfanyl}-1,3-thiazol-2-yl)cyclopropane-1-carboxamide,
QIIVJLHCZUTGSD-CUBQBAPOSA-N,
SCHEMBL1344892,
KS-00000XOP,
EX-A158,
C28H37N3O3S3,
AOB87320,
2527AH,
ABP000960,
MFCD21609257,
s2155,
ZINC70471849,
AKOS027314130,
BCP9000874,
CS-1281,
DB12284,
(1R,2S)-2-Cyclohexyl-1-(4-(cyclopropylsulfonyl)phenyl)-N-(5-((2-(1-pyrrolidinyl)ethyl)thio)-2-thiazolyl)cyclopropanecarboxamide,
BC638846,
HY-13529,
QC-11688,
SC-94261,
AB0165901,
FT-0773586,
LY2608204/,
W-5849,
J-690089,
BRD-K12068470-001-04-1,
(1r,2s)-2-cyclohexyl-1-(4-cyclopropanesulfonyl-phenyl)-cyclopropanecarboxylic acid [5-(2-pyrrolidin-1-yl-ethylsulfanyl)-thiazol-2-yl]-amide,
(1R,2S)-2-cyclohexyl-1-[4-(cyclopropylsulfonyl)phenyl]-N-[5-[[2-(1-pyrrolidinyl)ethyl]thio]-2-thiazolyl]-cyclopropanecarboxamide,
2,2'-[Oxybis(2,1-ethanediyloxy-5,2-pyridinediyl)]bis[6-(trifluoromethoxy)-1H-benzimidazole],
Cyclopropanecarboxamide, 2-cyclohexyl-1-[4-(cyclopropylsulfonyl)phenyl]-N-[5-[[2-(1-pyrrolidinyl)ethyl]thio]-2-thiazolyl]-, (1R,2S)-,
D0E1WH,
A11406,
Glucokinase activator (type 2 diabetes), Eli Lilly,
(1R,2S)-2-Cyclohexyl-1-[4-(cyclopropylsulfonyl)phenyl]-N-[5-[[2-(1-pyrrolidinyl)ethyl]thio]-2-thiazolyl]cyclopropanecarboxamide,